Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference GlobeNewswire - Mon Nov 24, 6:00AM CST

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat...

MCRB : 16.66 (-6.93%)
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Wed Nov 5, 6:00AM CST

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant...

MCRB : 16.66 (-6.93%)
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 GlobeNewswire - Thu Oct 30, 6:00AM CDT

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...

MCRB : 16.66 (-6.93%)
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 GlobeNewswire - Wed Oct 29, 6:00AM CDT

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria...

MCRB : 16.66 (-6.93%)
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant GlobeNewswire - Tue Oct 14, 6:00AM CDT

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from...

MCRB : 16.66 (-6.93%)
Seres Therapeutics Cuts Costs to Extend Cash Runway Tipranks - Sat Oct 4, 3:42PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Seres Therapeutics...

MCRB : 16.66 (-6.93%)
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway GlobeNewswire - Tue Sep 23, 6:00AM CDT

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell...

MCRB : 16.66 (-6.93%)
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Wed Aug 27, 6:00AM CDT

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright...

MCRB : 16.66 (-6.93%)
Seres Therapeutics: Q2 Earnings Snapshot AP - Wed Aug 6, 6:15AM CDT

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 16.66 (-6.93%)
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Wed Aug 6, 6:00AM CDT

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT)...

MCRB : 16.66 (-6.93%)
SANA : 5.13 (-0.97%)

Barchart Exclusives

Rate Decision, Tech Earnings and Other Key Things to Watch this Week Barchart - Sun Dec 7, 12:00PM CST
Markets face the year's final major policy week as the Federal Reserve's December meeting Wednesday afternoon will determine whether the central bank delivers another rate cut or pauses its easing cycle amid mixed economic signals and persistent inflation concerns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot